Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEBEL: Pembrolizumab in Elderly Advanced NSCLC
NCT03293680Phase 2Completed
- Sponsor
- Fundación GECP
- Start
- Jan 2017
- Primary completion
- Apr 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Fundación GECP. Started Jan 2017; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03293680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03293680.